Topotecan dosing guidelines in ovarian cancer: reduction and management of hematologic toxicity.
about
Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitroPhase I trial of autologous hematopoietic SCT with escalating doses of topotecan combined with CY and carboplatin in patients with relapsed or persistent ovarian or primary peritoneal carcinoma.Phase II study of topotecan and thalidomide in patients with high-risk myelodysplastic syndromes.Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma.Design, synthesis, and biological evaluation of O-2-modified indenoisoquinolines as dual topoisomerase I-tyrosyl-DNA phosphodiesterase I inhibitors.Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.Treatment of elderly cancer patients with chemotherapy.Optimal therapy for platinum-resistant recurrent ovarian cancer: doxorubicin, gemcitabine or topotecan?Safety of topotecan in the treatment of recurrent small-cell lung cancer and ovarian cancer.Patient selection and targeted treatment in the management of platinum-resistant ovarian cancer.Feasibility of extension of platinum-free interval with weekly bolus topotecan and subsequent platinum retreatment outcomes in recurrent ovarian cancer.Palliative chemotherapy for malignant ascites secondary to ovarian cancer.Prevention of carboplatin-induced hypersensitivity reactions in women with ovarian cancer.
P2860
Q24615499-EF31EC7D-2735-462D-BFEB-CC4C161DEB7FQ27851478-B39B87A6-1A6C-4099-BBD5-5546CB463D6AQ33153452-DD887EF6-8FA9-4650-8E0E-351B13DCC3B8Q33395016-64878C6A-12D8-4180-BD0D-4D2554607FE1Q33662415-B012C41B-3F16-40A0-808B-8F2D0EBF2DFBQ33780751-FF782542-F861-4100-9192-5F733A8F35D3Q36276360-F644E7BB-4E64-4E07-BDD9-CF355BE9B46CQ36488198-6E01B2E8-745A-4579-B48F-B8949168A56FQ36689071-E2BB1C0D-9EAC-47F9-89CA-C828E5127171Q37220528-AB235CDD-A8E3-4F41-B3BD-3CD2CD7FF587Q37728984-4B4A021A-DE8D-47A2-9180-C6A8732E8465Q37987902-89CD51E8-7CC0-47E1-985F-8C14C39E36E9Q39179349-79346B01-A103-4911-A4BF-C00324E9D6F1
P2860
Topotecan dosing guidelines in ovarian cancer: reduction and management of hematologic toxicity.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Topotecan dosing guidelines in ...... ement of hematologic toxicity.
@ast
Topotecan dosing guidelines in ...... ement of hematologic toxicity.
@en
type
label
Topotecan dosing guidelines in ...... ement of hematologic toxicity.
@ast
Topotecan dosing guidelines in ...... ement of hematologic toxicity.
@en
prefLabel
Topotecan dosing guidelines in ...... ement of hematologic toxicity.
@ast
Topotecan dosing guidelines in ...... ement of hematologic toxicity.
@en
P1433
P1476
Topotecan dosing guidelines in ...... ement of hematologic toxicity.
@en
P2093
Deborah K Armstrong
P356
10.1634/THEONCOLOGIST.9-1-33
P577
2004-01-01T00:00:00Z